ESMO 2021, News Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer Publish Date September 20, 2021 There was no improvement in overall survival with bevacizumab.
ESMO 2021, News Immunotherapy Significantly Improved Survival in Recurrent/Metastatic Cervical Cancer Publish Date September 20, 2021 The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.